Friday - May 01, 2026

Category Archives: Marketing & Sales

Schizophrenia Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Teva Pharma, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharma, Reviva Pharma, Minerva Neurosciences

The Key Schizophrenia Companies in the market include – Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, AstraZeneca, Eli Lilly … Continue reading →

Down Syndrome Pipeline Enters a New Phase of Innovation with Targeted Therapies and Advancing Clinical Programs from Aelis Farma, AC Immune, and Perha Pharmaceuticals | DelveInsight

Down Syndrome Clinical Trial Key Down Syndrome Companies are Aelis Farma, AC Immune SA, Perha Pharmaceuticals, and others The Down Syndrome therapeutic landscape is steadily evolving as pharmaceutical and biotechnology companies intensify their research efforts to address the complex genetic … Continue reading →

BK Virus Infection Pipeline Advances Toward Targeted Therapeutics by 2026 with Emerging Innovations from AiCuris, Memo Therapeutics, and Vera Therapeutics | DelveInsight

BK Virus Infection Clinical Trial Key BK Virus Infection Companies are AiCuris Anti-infective Cures AG, Memo Therapeutics AG, Vera Therapeutics, and others. The BK Virus (BKV) Infection therapeutic landscape is steadily evolving, driven by a focused pipeline of innovative drug … Continue reading →

Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight

Asthma Clinical Trials Key Asthma Companies include Generate Biomedicines, AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Pfizer, Sanofi, Amgen, and others The global asthma therapeutic landscape is undergoing a profound transformation, driven by an expanding pipeline of innovative therapies and … Continue reading →

Hyperoxaluria Pipeline Set for Breakthrough Innovation by 2026 with Advancements in Gene Editing and Metabolic Therapies from Arbor Biotechnologies, META Pharmaceuticals, and Biocodex | DelveInsight

Hyperoxaluria Clinical Trial Key Hyperoxaluria Companies include Arbor Biotechnologies, META Pharmaceuticals, Biocodex, and many more The Hyperoxaluria therapeutic landscape is witnessing a transformative shift, driven by cutting-edge research and the emergence of targeted therapies aimed at addressing the root causes … Continue reading →

Hypersomnia Pipeline Set for Steady Expansion Through 2026 with Emerging Orexin-Based Therapies and Clinical Advancements from Takeda, Centessa Pharmaceuticals, and Alkermes | DelveInsight

Hypersomnia Clinical Trial Key Hypersomnia Companies are Takeda, Centessa Pharmaceuticals, Alkermes, and others The Hypersomnia therapeutic landscape is undergoing a gradual yet meaningful transformation, driven by increasing clinical research, deeper understanding of sleep-wake neurobiology, and the emergence of targeted therapies. … Continue reading →

Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus

There are 70+ key companies, including Belite Bio, Alkeus Pharmaceuticals, Stealth BioTherapeutics, Ocugen, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and Novartis, developing therapies for Dry Age-Related Macular Degeneration. Multiple candidates are advancing through late-stage Phase III trials, reflecting … Continue reading →

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path

Antisense Oligonucleotide Therapeutics Pipeline Insight The Antisense Oligonucleotide landscape features 70+ key companies, including Novartis, Wave Life Sciences, Bio-Path Holdings, and others, advancing over 90 pipeline drugs. Companies like Novartis and Wave Life Sciences are currently leading with candidates in … Continue reading →

Acute Lymphocytic Leukemia Pipeline Grows as 120+ Pharma Companies Advance Novel Blood Cancer Therapies, Finds DelveInsight | Ascentage Pharma, Hebei Senlang Biotechnology, Amgen, Servier

Acute Lymphocytic Leukemia (ALL) Pipeline Insight There are 120+ key companies, including Ascentage Pharma, Hebei Senlang Biotechnology, Amgen, Servier, Beam Therapeutics, Janssen, Orca Bio, and others, developing therapies for Acute Lymphocytic Leukemia, with several candidates such as Olverembatinib and Orca-T … Continue reading →